ArticleBMJ open respiratory research2019

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Toby M Maher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.